| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 05/11/2005 | CN1613467A Composition for restoring consciousness and improving memory quickly |
| 05/11/2005 | CN1613457A Yinping yangmi pills |
| 05/11/2005 | CN1613443A Emodin application for preparaing medicine with nervous centralis erethism inhibition |
| 05/11/2005 | CN1200932C Substituted phenylcyclohexane carboxylic acid amides that have an adenosine uptake inhibiting effect |
| 05/11/2005 | CN1200747C Low dose estrogen interupted hormone replacement therapy |
| 05/11/2005 | CN1200734C Treatment of refractory human tumors with epidermal growth factor receptor antagonists |
| 05/11/2005 | CN1200726C Treatment of tumors by administration of growth hormone releasing compounds and their antagonists |
| 05/11/2005 | CN1200719C Health food capable of regulating blood lipoid and delaying senility |
| 05/11/2005 | CN1200714C Use of diterpenoid triepoxides as anti-proliferative agent |
| 05/11/2005 | CN1200713C New (aminopropyl) methylphosphinic acids |
| 05/11/2005 | CN1200704C Appliance of probucol monoesters for treatment of cardiovascular and inflammatory disease |
| 05/11/2005 | CN1200703C Use of pentanoate derivant |
| 05/11/2005 | CN1200702C Use of NMDA antagonist for treatment of irritable bowel syndrome |
| 05/11/2005 | CN1200701C Compositions for reducing incidence of necrotizing enterocolitis |
| 05/11/2005 | CN1200687C Composition containing N-vinyl iminazole polymer or copolymer and oxidation sensitive hydrophilic active ingredients for cosmetics and/or dermatology |
| 05/11/2005 | CN1200684C Compositions comprising organosiloxane resins for delivering oral care substances |
| 05/11/2005 | CN1200673C Antimicotic nail varnish composition |
| 05/11/2005 | CN1200654C Method and device for preparing dental implant by immersion in mesenchymal cell culture |
| 05/10/2005 | US6891066 For therapy of cancer, restenosis, psoriasis, autoimmune disease, atherosclerosis, osteoarthritis, rheumatoid arthritis, heart failure, chronic pain, and neuropathic pain |
| 05/10/2005 | US6891028 Nucleic acids encoding transferrin receptor-like proteins |
| 05/10/2005 | US6890949 Amino ceramide-like compounds and therapeutic methods of use |
| 05/10/2005 | US6890943 3-acylated pyridoxal derivatives used to treat vitamin B6 deficiency, cardiovascular diseases, melanoma and other related diseases |
| 05/10/2005 | US6890940 Immoglobulin E (IgE) antibody production inhibitor; treating allergic immune diseases such as asthma, dermatitis, inflammatory bowel disease and allergic opthalmopathy |
| 05/10/2005 | US6890939 Aminopyrrolidine sulfonamides as serine protease inhibitors |
| 05/10/2005 | US6890938 Antiinflammatory agents |
| 05/10/2005 | US6890937 Inhibiting the activity of one or more of MMP-2, MMP-9 and MMP-13, while exhibiting substantially less inhibitory activity against MMP-1 |
| 05/10/2005 | US6890934 Hypoglycemic agents; muscle relaxants; bronchodilator agents; antiallergens |
| 05/10/2005 | US6890931 Methods of treating disorders with group I mGluR antagonists |
| 05/10/2005 | US6890928 Aromatic sulfone hydroxamic acids and their use as protease inhibitors |
| 05/10/2005 | US6890927 Tartrate salts of 5,8, 14-triazateracyclo[10.3.1.02,11 04.9]-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof |
| 05/10/2005 | US6890924 Substituted bicyclic derivatives for the treatment of abnormal cell growth |
| 05/10/2005 | US6890922 For treatment of erectile dysfunction as well as female sexual dysfunction, incontinence, and hypertrophy of the prostate; inhibitors of cGMP-metabolizing phosphodiesterases (cGMP= cyclic guanosine monophosphate) |
| 05/10/2005 | US6890920 Therapeutic treatment of asthma, chronic obstructive pulmonary disease, rhinorrhea due to the common cold, rhinitis |
| 05/10/2005 | US6890917 Particularly significant oral in vivo activity |
| 05/10/2005 | US6890915 Hydantoins and related heterocycles as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme (TACE) |
| 05/10/2005 | US6890900 Methods for treating or preventing diseases of the oral cavity |
| 05/10/2005 | US6890899 A lipolytic or lipid mobilising factor (LMF) produced by the cachexia-inducing murine tumor MAC16; weight reduction or controlling obesity; administering a Zn-alpha 2-glycoprotein |
| 05/10/2005 | US6890897 In combination with an osteoinductive protein and a bone morphogenetic protein or a hedgehog protein to induce osteogenesis; biocompatible or biodegradable matrix |
| 05/10/2005 | US6890751 NRG-2 nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods |
| 05/10/2005 | US6890731 For drug screeing/therapy of diseases; bacteriophages |
| 05/10/2005 | US6890457 Infrared radiation emitting ceramic powders comprising zirconium or radium and oxides of silicon, aluminum, iron, titanium, calcium, magnesium, potassium and sodium, used for joining wood, paper, leather, metals or plastics; radiotherapy |
| 05/10/2005 | CA2407562C Tryptophan source from plants and uses therefor |
| 05/10/2005 | CA2320474C 6,9-disubstituted 2-[trans-(4-aminocyclohexyl)amino]purines |
| 05/10/2005 | CA2303801C Aromatic c16-c20-substituted tetrahydro prostaglandins useful as fp agonists |
| 05/10/2005 | CA2279743C Pharmaceutical composition of hedgehog proteins and use thereof |
| 05/10/2005 | CA2278290C Quinazolinone compounds |
| 05/10/2005 | CA2250569C Novel phenanthridines substituted in the 6 position |
| 05/10/2005 | CA2246753C Non-peptidyl vasopressin v1a antagonists |
| 05/10/2005 | CA2116559C Treatment to prevent loss of and/or increase bone mass in metabolic bone diseases |
| 05/10/2005 | CA2111193C Tissue treatment composition comprising fibrin or fibrinogen and biodegradable and biocompatible polymer |
| 05/10/2005 | CA2097044C Cyclopentane- and -pentene-.beta.-amino acids |
| 05/10/2005 | CA2067330C Herpes simplex virus type 1 mutant |
| 05/06/2005 | WO2005039638A2 Therapeutic agent for heart failure comprising an angiotensin ii receptor antagonist and a matrix metalloproteinase inhibitor |
| 05/06/2005 | WO2005039621A1 Fibroblast-mobilizing agent containing g-csf and wound remedy |
| 05/06/2005 | WO2005039602A1 Pharmacologically functional water and use thereof |
| 05/06/2005 | WO2005039599A1 Matrix metalloprotease inhibitor containing polylactic acid mixture |
| 05/06/2005 | WO2005039541A1 Coenzyme q10 enclosing capsule |
| 05/06/2005 | WO2004002939A3 Aminoalcohol derivatives |
| 05/06/2005 | WO2003068746A8 Aryl ureas as kinase inhibitors |
| 05/06/2005 | WO2003068146A3 Identification of actinobacillus actinomycetemcomitans antigens for use in the diagnosis, treatment, and monitoring of periodontal diseases |
| 05/06/2005 | WO2003018606A3 Casein derived peptides and uses thereof in therapy |
| 05/06/2005 | WO2002095007A3 Conjugates activated by cell surface proteases and therapeutic uses thereof |
| 05/06/2005 | CA2543817A1 Fibroblast-mobilization agent containing a g-csf for repair of myocardial infarct lesion |
| 05/06/2005 | CA2543404A1 Novel inhibitor of the formation of advanced glycation end product and aldose reductase inhibitor |
| 05/06/2005 | CA2542716A1 Compounds having crth2 antagonist activity |
| 05/06/2005 | CA2542412A1 Use of xenon for the prevention of programmed cell death |
| 05/06/2005 | CA2541894A1 Amino alcohol derivative, medicinal composition containing the same, and use of these |
| 05/05/2005 | US20050096479 Novel succinate salt of O-desmethyl-venlafaxine |
| 05/05/2005 | US20050096473 Reacting 1,1'-thiocarbonyldiimidazole with an aryl amine, e.g., benzylamine, to form 1830 thiourea (or urea)prodoucts; high speed, automatic process; anticarcinogenic agents, leukemia; enzyme inhibitors for HIV reverse transcriptase (polymerase) |
| 05/05/2005 | US20050096469 Mono-ester and asymmetrically substatuted di-ester pro-drugs of dopamide d1 receptor agonists |
| 05/05/2005 | US20050096468 Inhibitors of histone deacetylase |
| 05/05/2005 | US20050096460 Beta-amyloid peptide-binding proteins and polynucleotides encoding the same |
| 05/05/2005 | US20050096457 Peptide substrates and fusion polypeptide substrates comprising a beta -secretase cleavage site wherein a human Aspartyl protease cleaves the peptide between P1 and P1, the rate of which cleavage is used to identify modulators of Alzeimer's disease, neurofibrillary tangles, gliosis and neuronal loss |
| 05/05/2005 | US20050096388 Compositions and methods for treating or preventing diseases of body passageways |
| 05/05/2005 | US20050096382 Agent for preventing recurrence of cerebrovascular disorder and agent for ameliorating troubles following cerebrovascular disorder and inhibiting progress thereof |
| 05/05/2005 | US20050096359 melanocortin receptor agonist, antagonist; preventing or treating inflammatory diseases, AIDS, obesity, bulimia, anorexia or sexual dysfunction; N-(2-aminoethyl)-3'-[1-{N-(1-benzylpiperidin-4-yl)-N-(2-naphthylacetyl)aminoethyl][1,1'-biphenyl)-2-carboxamide dihydrochloride |
| 05/05/2005 | US20050096356 2-[[6-Methoxy-3-pyridinyl]methyl]amino-N-[3-(trifluoromethyl)phenyl]benzamide hydrochloride salt or its tautomer; treating retinopathy or age-related macula degeneration |
| 05/05/2005 | US20050096347 Beta3-Adrenoreceptor agonists, agonist compositions and methods of using |
| 05/05/2005 | US20050096335 Heteroaryl - fused nitrogen heterocycles as therapeutic agents |
| 05/05/2005 | US20050096334 Use of substance P antagonists for the treatment of chronic fatigue syndrome and/or fibromyalgia and use of NK-1 receptor antagonists for the treatment of chronic fatigue syndrome |
| 05/05/2005 | US20050096322 Nitrogen-containing heterocyclic compound |
| 05/05/2005 | US20050096320 potent inhibitors of cyclic guanosine 3',5'-monophosphate-metabolizing phosphodiesterases (cGMP-PDEs)/phosphodiesterase isoenzymes PDE-I, PDE-II, PDE-V; therapeutic, antiaggregatory, antithrombotic, antiproliferative, antivasospastic, vasodilatory, natriuretic and diuretic effects; erectile dysfunction |
| 05/05/2005 | US20050096316 Quinoline derivatives(2) |
| 05/05/2005 | US20050096313 Substance P; 2-(phenyl)-4-(3-oxo-piperazin-1-yl-)-piperidine-1-carboxylic acid; benzyl-methylamide; antagonists of the NK1 receptor; antidepressant, antiolytic; antiemetic |
| 05/05/2005 | US20050096312 Antiserotonine agents; antidepressants; eating disorders; anxiolytic agents; sleep disorders; gastrointestinal disorders; cardiovascular disorders; muscular disorders; endocrine system diseases; muscular disorders; psychological disorders |
| 05/05/2005 | US20050096310 Antagonist of phosphorylation of myosin regulatory light chain, enzyme inhibitors; therapeutic treatment of glaucoma, bronchial asthma, chronic obstructive pulmonary disease, nervous system disorders; 4-(2,3-dihydro-1,5-diazaphenalen-1-yl)cyclohexylamine |
| 05/05/2005 | US20050096293 Analogs of nitrobenzylthioinosine |
| 05/05/2005 | US20050096271 Fusion of polypeptides and immunoglobulin protein; immunotherapy ; antiallergens; antiarthritic agents; anticancer agents; antiinflammatory agents |
| 05/05/2005 | US20050096268 Treatment of fibrosis by antagonism of IL-13 and IL-13 receptor chains |
| 05/05/2005 | US20050096267 Fusion protein contains amino acid sequence with 9 to 13 residues of arginine; antagonist of Nuclear Factor Activated T cell (NFAT); short effectiveness and no side effects or antigenicity; signal sequence, immunosuppressants, biodrugs |
| 05/05/2005 | US20050096266 Administering trypsin inhibitor and amino acid |
| 05/05/2005 | US20050096256 Compositions for manipulating the lifespan and stress response of cells and organisms |
| 05/05/2005 | US20050096253 Utilization of inhibitors of rho-kinases for stimulating nerve growth, inhibiting scar tissue formation and/or reducing a secondary lesion |
| 05/05/2005 | US20050095681 Intracellular modulators of apoptopic cell death pathways |
| 05/05/2005 | US20050095663 Via 6-(4-chlorophenyl)-2-(2'-pentyn-4'-ene-1-yl)-3(2H)-pyridazinone for inhibition of delta-9 fatty acid desaturase |
| 05/05/2005 | US20050095612 isolated antibody that specifically binds to polypeptides for diagnosing, preventing and treating autoimmune, cancer and transplant disorders; wound healing agents |
| 05/05/2005 | US20050095304 Composition and method for smoke detoxification |
| 05/05/2005 | US20050095291 Tamper-resistant oral opioid agonist formulations |
| 05/05/2005 | US20050095290 comprising pharmacologically active substance, drug absorbefacient and taurine compound or polyamine; suppressing or preventing damage of the intestinal mucous membrane |
| 05/05/2005 | US20050095248 Use of inhibitor of cathepsin S based upon peptide sequence which comprises at least about 2-20 consecutive residues from preferred invariant chain cleavage site of cathepsin S, spanning from residue 68 to residue 90 of specified sequence |